COMPANY PROFILE

Daicel

Explore full profile

Diversified chemical company that has its roots in celluloid manufacturing

Osaka, JapanFounded 1919Health

Valuation $2.5–5B Last recorded · 2026

Revenue $1–5B Latest reported FY

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 1919
Headquarters: Osaka, Japan
Employees: 110
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sector: Health
Business model: Manufacturing
Client focus: b2b
Investment activity: 2 companies, latest Oct 2023
Capital deployed: $14M
Preferred round: LATE VC
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jul 2025	$33M	$133M	Undisclosed	—
IPO✓Exit	May 1949	$0	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Daicel website traffic

Latest recorded traffic for Daicel is 38K monthly website visits, down 19.1% over the last three months. Daicel's team declined 14.1% over the past year.

Latest monthly visits38K 3-month web change-19.1% 1-year team growth-14.1%

Monthly website visitsOct 2020–Sep 2022

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational